<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370110</url>
  </required_header>
  <id_info>
    <org_study_id>ITODG04-02</org_study_id>
    <nct_id>NCT00370110</nct_id>
  </id_info>
  <brief_title>Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Single Center, Parallel Group Study to Evaluate the Effects of Itopride (100 mg and 200 mg t.i.d.) on Gastric Motor and Sensory Functions in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Itopride is a new compound that is already marketed in Japan and in some countries of Eastern&#xD;
      Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.&#xD;
      Due to inadequate gastric emptying, these patients often have symptoms of bloating, nausea&#xD;
      and vomiting following ingestion of a meal. This is a randomized, parallel group, two dose&#xD;
      double blind, placebo-controlled study evaluating the effects of itopride (100 mg and 200 mg&#xD;
      three times daily) and placebo on gastric motor and sensory functions in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to compare the effects of two itopride doses (100 mg and 200 mg three times daily)&#xD;
      and placebo on gastric emptying and small bowel transit, gastric accommodation, and&#xD;
      postprandial symptoms in female and male healthy volunteers, the following methods, which&#xD;
      have been extensively used and validated in the laboratory, will be used:&#xD;
&#xD;
      Scintigraphic gastric emptying of solids and small bowel transit; single photon emission&#xD;
      computed tomography to measure gastric accommodation; and the nutrient drink test to measure&#xD;
      maximum tolerated volume and postprandial symptoms.&#xD;
&#xD;
      Based on data acquired using the same methods in the laboratory, the sample size of 15&#xD;
      subjects per group provides 80% power to detect an effect size of 16% in the primary endpoint&#xD;
      of the study, that is a change in gastric volume (postprandial - fasting). This magnitude of&#xD;
      change is considered clinically relevant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>one week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Small bowel transit</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric accommodation</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial symptoms</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Itopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride 100 mg</intervention_name>
    <description>100 mg three times daily</description>
    <arm_group_label>Itopride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride 200 mg</intervention_name>
    <description>200 mg three times daily</description>
    <arm_group_label>Itopride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Non-pregnant, non-breastfeeding females 2.18 years of age or older 3.Body mass index&#xD;
        between 20 and 32 kg/m2 4.No alarm indicators on clinical assessment (weight loss of more&#xD;
        than 7 kg, bleeding, recent recurrent vomiting, progressive dysphagia).&#xD;
&#xD;
        5.No history suggestive of small bowel obstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have any gastrointestinal symptoms. Do not fulfill the criteria for the&#xD;
             irritable bowel syndrome or functional dyspepsia clinically&#xD;
&#xD;
          2. Patients with a clinical diagnosis of gastroparesis or an alternative underlying&#xD;
             disease that could be responsible for disturbed gastric function e.g. diabetes,&#xD;
             post-vagotomy, post-fundoplication&#xD;
&#xD;
          3. Abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, caesarian&#xD;
             section or tubal ligation&#xD;
&#xD;
          4. Positive symptoms on an abridged bowel disease questionnaire&#xD;
&#xD;
          5. Use of medications that may alter gastrointestinal motility including metoclopramide,&#xD;
             domperidone, tegaserod; acetaminophen and ibuprofen will be allowed&#xD;
&#xD;
          6. Current use of medications which may interact with the study medications&#xD;
&#xD;
          7. Patients who have taken any investigational medications within the past 30 days&#xD;
&#xD;
          8. Over the counter medication (except multivitamins) within 7 days of the study&#xD;
&#xD;
          9. Chronic gastrointestinal illness or any systemic disease that could affect&#xD;
             gastrointestinal motility for controls&#xD;
&#xD;
         10. Known intolerance or allergy to eggs, milk and Ensure&#xD;
&#xD;
         11. History of chronic diarrhea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J. Talley, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 28, 2006</study_first_submitted>
  <study_first_submitted_qc>August 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2006</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

